To explore the immunological mechanisms underlying the enhanced tumor-specific immune response, we assessed the effects of combination therapy on the proportions of MDSCs (CD11b+Gr1+), M2 macrophages (CD11b+F4/80+CD206+ cells), and Tregs (CD4+CD25+FoxP3+ cells) in splenocytes. The gene discussed is MRC1; the disease is neoplasm.